Merck’s Efavirenz Licensing, Not Pricing, Targeted By South African AIDS Group
Executive Summary
An AIDS activist group in South Africa is going after Merck for its marketing of the anti-retroviral efavirenz. But unlike past battles over AIDS drugs, the group is not complaining about pricing but rather Merck's licensing of the medicine to only two companies